Pain Clinical Trial
Official title:
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain
Over the last years a rising medical need for treatment of chronic pain was identified. Based on previous findings indicating the pain modulating effects of cannabinoids in chronic pain disorders, this clinical trial investigates the long term efficacy and tolerability of the THC-focused nano endocannabinoid system modulator AP707 in patients with chronic back pain disorders. Patients receive AP707 or placebo over the course of 14 weeks as an add-on to the standard of care. Changes in pain intensity, quality of life and sleep and others measures are monitored through different scales to assess the efficacy of AP707 in patients with chronic back pain.
Status | Recruiting |
Enrollment | 558 |
Est. completion date | December 31, 2024 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed and dated informed consent form 2. Patients with chronic back pain since at least 3 months 3. Female and male patients (> 18 years) 4. Patients with more than 1 year life expectancy 5. Patients with optimized sCPT on study entry as defined in section 3.1.1 and section 3.1.3 of the study protocol 6. Willingness of study patients of both sexes to use reliable contraception during study participation and for three months after taking the last study medication 7. Good command of German language, in order to understand questionnaires in German 8. Current moderate to severe pain with pain intensity > 5 on Numeric Rating Scale (NRS, 0 - 10) and thus an existing need for further pain therapy 9. Completed QUISS (Quantification Inventory for Somatoform Syndromes) questionnaire with 45 or less score points 10. Completed painDETECT questionnaire with 20 or more score points Exclusion Criteria: 1. Medical history of hypersensitivity or intolerance to the investigational product or its ingredients or to ingredients of similar chemical structure 2. Known intolerance to cannabinoids or cannabis products. 3. Participation in another clinical trial within the last four weeks prior to inclusion. 4. Pregnant or nursing women (as excluded by pregnancy testing at visit 1). 5. Other medical conditions that do not allow the trial subject to appraise the nature, scope, and potential consequences of the clinical trial 6. Indications that the trial subject is unlikely to comply with the study protocol (e.g., unwillingness to cooperate) 7. Known use of medicinal cannabis products within the last 8 weeks 8. Active malignant tumor disease, tumor pain, or other dominant severe pain other than that of the study indication 9. Known history of severe liver or kidney diseases 10. Known history of severe cardiovascular disease 11. Known history of or acute mental illness such as severe depression, psychosis, bipolar disorder, mania, anxiety, or obsessive-compulsive disorder 12. Known history of addictive disease (e.g., alcohol, medication, drug addiction) 13. Answered during Screening less than 12 times of 18 the pain intensity (NRS) inquiry 14. Laboratory liver values: Alanine aminotransferase (ALT, GPT) > 3 x ULN (Upper Limit of Normal range), Aspartate aminotransferase (AST, GOT) > 3 x ULN, Alkaline phosphatase (AP) > 2.5 x ULN, and for bilirubin > 1.5 x ULN 15. Laboratory renal value: Serum creatinine > 1.5 ULN |
Country | Name | City | State |
---|---|---|---|
Germany | Klinikum Rechts der Isar (Zentrum für Interdisziplinäre Schmerztherapie) | Munich | Bavaria |
Lead Sponsor | Collaborator |
---|---|
Apurano Pharmaceuticals GmbH |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number and severity of adverse events (AE) | Week 1 to 52 | ||
Primary | Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 14 (end of first treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo) | Once daily in week 4 and 14 | ||
Secondary | Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 26 (end of second treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo) | Once daily in week 4 and 26 | ||
Secondary | Change in pain level on the Numeric Rating Scale (NRS, 0-10) between baseline and at treatment week 52 (end of third treatment phase) in comparison of study arm 1 (verum) and study arm 2 (placebo) | Once daily in week 4 and 52 | ||
Secondary | Change in the pain score of the Neuropathic Pain Symptom Inventory (NPSI) questionnaire between baseline and at treatment week 14, treatment week 26 and treatment week 52 in comparison of study arm 1 (verum) and study arm 2 (placebo) | Once in week 1, 14, 26 and 52 | ||
Secondary | Change in pain level on the Numeric Rating Scale (0-10) between baseline and in treatment week 5, 11, 18, 22, 30, 34, 43, 47 in comparison of study arm 1 (verum) and study arm 2 (placebo) | Several times weekly in week 4, 5, 11, 18, 22, 30, 34, 43 and 47 | ||
Secondary | Responder analysis for endpoints 1), 2), 3) and 4) for treatment week 14, 26 and 52 | Proportion of patients who experienced > 30 % improvement in pain score (Numeric Rating Scale)
Proportion of patients who experienced > 40 % improvement in pain score (Numeric Rating Scale) Proportion of patients who experienced > 50 % improvement in pain score (Numeric Rating Scale) |
Week 14, 26 and 52 | |
Secondary | Change in sCPT (percentage of change in dosage and percentage of change in combination of analgesic measures) in both study arms from start to week 14 | Week 14 | ||
Secondary | Change in pain-related impairment according to von Korff et al. from start to week 14, 26, and 52 | Week 1, 14, 26 and 52 | ||
Secondary | Change in psychological distress using Depression Anxiety Stress Scales Short Form (DASS-21) questionnaire from start to week 14, 26, and 52 | Week 1, 14, 26 and 52 | ||
Secondary | Change of Patient Global Impression of Change (PGIC) from start to week 14, 26, and 52 | Week 14, 26 and 52 | ||
Secondary | Change in quality of life using the Veterans RAND (VR-12) questionnaire from start to week 14, 26, and 52 | Week 1, 14, 26 and 52 | ||
Secondary | Change in sleep quality using the Regensburg Insomnia Scale (RIS) from start to week 14, 26, and 52 | Week 1, 14, 26 and 52 | ||
Secondary | Change in pain score of the Brief Pain Inventory - Short Form (BPI-SF) questionnaire from start to week 14, 26, and 52 | Week 1, 14, 26 and 52 | ||
Secondary | Area under NRS-curve until treatment week 5, 11, 14, 18, 22, 26, 30, 34, 39, 43, 47, 52 | Week 5, 12, 18, 22, 26, 30, 34, 39, 43, 47 and 52 | ||
Secondary | Change in VR-12 components (physical component summary PCS, mental component summary MCS) from start to week 14, 26, and 52 | Week 1, 14, 26 and 52 | ||
Secondary | Number of patients with rescue medication over the course of the clinical trial and within periods: until treatment week =5, =11, =14, =18, =22, =26, =30, =34, =43, =47, =52 | Week 5, 11, 14, 18, 22, 26, 30, 34, 43, 47 and 52 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|